Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
The Lancet. Oncology|August 19, 2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysisScott J Antonia, Hossein Borghaei, Suresh S Ramalingam, et al.The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline UpdateNasser H Hanna, Bryan J Schneider, Sarah Temin, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stabilityYujie Zhao, Jarushka Naidoo, Michael Conroy, et al.The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.American Journal of Respiratory Cell and Molecular Biology|October 10, 2025
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor PneumonitisMohammad I Ghanbar, Andres Villabona-Rueda, Nicolas Philip, et al.The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as BiomarkersNeal Ready, Matthew D Hellmann, Mark M Awad, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.Pageof 7